NeuroSense Therapeutics (NRSN) Corporate presentation summary

Company overview and therapeutic focus

• Clinical-stage biotech developing novel therapies for neurodegenerative diseases with high unmet need, focusing on ALS with a Phase 3-ready asset, PrimeC.

• ALS is a rapidly progressing, terminal disease with a median survival of 3 years and limited treatment options, affecting over 200,000 patients worldwide.

PrimeC mechanism and clinical rationale

• PrimeC is a patented, fixed-dose combination of two approved drugs with synchronized pharmacokinetics, targeting neuroinflammation, iron dysregulation, miRNA regulation, and TDP-43 pathology.

• Demonstrated multi-targeted action and synergy, achieving therapeutic effects not seen with either agent alone, with patent protection until 2042.

Clinical trial results and efficacy

• Phase 2b PARADIGM trial showed PrimeC met its primary endpoint, significantly reducing TDP-43 (p=0.04), a key ALS pathology marker.

• PrimeC slowed disease progression by ~33% over 18 months (p=0.007) and provided a median survival advantage of ~15 months (p=0.02) compared to placebo.

• Safety profile was favorable, with most adverse events mild to moderate and only two transient, reversible serious adverse events.